Treatment with doxorubicin plus trabectedin (Yondelis), followed by trabectedin maintenance, improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic or ...

Discover comprehensive details about Trabectedin, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Combining trabectedin and olaparib showed marginal improvement in progression-free survival for advanced soft tissue sarcomas, with notable benefits in specific subgroups. Patients with PARP1 ...

Please provide your email address to receive an email when new articles are posted on . The antitumor drug trabectedin demonstrated superior disease control compared with conventional chemotherapy ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of trabectedin, having considered evidence on the nature of advanced soft tissue sarcoma and the value placed ...

Soft tissue sarcomas (STS) are a complex, heterogeneous group of more than 50 neoplasms of mesenchymal origin. According to the American Cancer Society, in 2015, approximately 11,930 patients in the ...

November 10, 2006 (New York) –- A new phase 2 trial has confirmed the findings of previous trials showing that the investigational drug trabectedin ( Yondelis, PharmaMar and Johnson & Johnson) is ...

• Trabectedin injection should be given directly into the vein through a separate central venous line very slowly for 24 hours. • Trabectedin powder for reconstitution should be mixed with 20 ml of ...

Chicago and Madrid, June 1st 2015: PharmaMar today announced data from a Phase 2 study in patients with sarcomatoid/biphasic malignant pleural mesothelioma showing that 41.2% (95% CI: 18.4-67.1) of ...

Janssen Research & Development, LLC (Janssen) announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival (PFS) with ...

Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada ...